Extensive Savings Remain Elusive 10 Years Into Biosimilar Era With Chart: Increased Biosimilar Use Could Offer Significant Savings for Employers
Biosimilar medications can offer meaningful cost savings for payers, but market and regulatory barriers are still preventing them from realizing their full economic potential, according to a March 31 Johns Hopkins University study funded by the ERISA Industry Committee (ERIC), a lobbying group for companies managing self-funded health insurance plans.
Biosimilars have demonstrated the potential to save patients money in the studied drug categories, according to Mariana Socal, a physician and researcher at the Johns Hopkins Bloomberg School of Public Health and one of the study’s authors.
© 2024 MMIT